Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4YPG

Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody

4YPG の概要
エントリーDOI10.2210/pdb4ypg/pdb
分子名称Sifalimumab light chain, Sifalimumab heavy chain, Interferon alpha-2, ... (5 entities in total)
機能のキーワードtherapeutic mab, ifn-alpha2a, immune system
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数6
化学式量合計131149.01
構造登録者
Oganesyan, V.,Dall'Acqua, W.F. (登録日: 2015-03-12, 公開日: 2015-05-06, 最終更新日: 2024-10-23)
主引用文献Oganesyan, V.,Peng, L.,Woods, R.M.,Wu, H.,Dall'Acqua, W.F.
Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab.
J.Biol.Chem., 290:14979-14985, 2015
Cited by
PubMed Abstract: We report the three-dimensional structure of human interferon α-2A (IFN-α2A) bound to the Fab fragment of a therapeutic monoclonal antibody (sifalimumab; IgG1/κ). The structure of the corresponding complex was solved at a resolution of 3.0 Å using molecular replacement and constitutes the first reported structure of a human type I IFN bound to a therapeutic antibody. This study revealed the major contribution made by the first complementarity-determining region in each of sifalimumab light and heavy chains. These data also provided the molecular basis for sifalimumab mechanism of action. We propose that its interferon-neutralizing properties are the result of direct competition for IFN-α2A binding to the IFN receptor subunit 1 (IFNAR1) and do not involve inhibiting IFN-α2A binding to the IFN receptor subunit 2 (IFNAR2).
PubMed: 25925951
DOI: 10.1074/jbc.M115.652156
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3 Å)
構造検証レポート
Validation report summary of 4ypg
検証レポート(詳細版)ダウンロードをダウンロード

238895

件を2025-07-16に公開中

PDB statisticsPDBj update infoContact PDBjnumon